January/February 2011, Vol 4, No 1
Research and development (R&D) activities in an era of globalization encounter a mosaic of providers, products, services, and intermediaries; regulatory and other government institutions; and consumers. Within the next 10 years, new product introductions within the United States and Western Europe in particular must navigate through a labyrinth of payers and purchasers, address the realities of transparent pricing and rule-driven business practices, and provide research and data as a differentiator of sales and marketing initiatives.
When Information Is Insufficient: Inspiring Patients for Medication Adherence and the Role of Social Support Networking
According to the World Health Organization (WHO), “Without a system that addresses the determinants of adherence, advances in biomedical technology will fail to realize their potential to reduce the burden of chronic illness.”1 The WHO has recommended that adherence challenges are most effectively solved by individualized interventions addressing multiple factors impeding adherence.1 In its report, Adherence to Long-Term Therapies: Evidence for Action, the WHO has identified 5 interactive “dimensions” or factors affecting adherence, including1:<
Health Plans Must “COPE” with Chronic Diseases
Comparative effectiveness research (CER) received a boost last year by the Patient Protection and Affordable Care Act as an approach that will help to identify best therapies and will also work to reduce costs by improving outcomes when best therapies are used.
Addressing Costs and Continuity of Care through Innovative Solutions for Infused Therapies: A Collaborative Experience with Infliximab
Growth in specialty pharmaceuticals (including biologic therapies) continues to outpace traditional small molecules,1 and many of the newly developed specialty products will be infused. At the start of the fourth quarter of 2009, at least 19 infused specialty therapies were waiting for approval by the US Food and Drug Administration or were in phase 3 clinical trials.2 Therefore, managing the costs associated with infused therapies continues to increase in importance for private and public health insurance plans.
New Strategies Needed to Combat Increasing Costs and Optimize Use of Infused Therapies
Despite educational programs, social stigma, and a plethora of popular diets, many American children—and their parents—remain far too heavy. The number of obese children has more than tripled since 1980.1 The good news is that obesity levels appear to be leveling off or even declining in some groups.2 The bad news is that many of our children are still severely overweight.
Results 1 - 6 of 6